Opinion|Videos|August 12, 2024
Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations
Author(s)Paolo Tarantino, MD
Paolo Tarantino, MD, discusses risk factors in early breast cancer, NCCN guideline-recommended therapies, and the transformative impact of HER2-targeted treatments over the past decade.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the risk factors and clinical characteristics that define high-risk early breast cancer, such as tumor size, nodal status, hormone receptor status, and residual disease after neoadjuvant therapy.
- How should clinicians approach risk stratification in early breast cancer to identify high-risk patients who may benefit from more aggressive treatment?
- Please provide a brief overview of treatment options in HER2+ breast cancer.
- Please highlight the NCCN guideline recommendations for managing early breast cancer, particularly Category 1 preferred options.
- How have the available HER2-targeted therapies changed the treatment landscape for patients with HER2+ breast cancer over the past decade or so?
- What are the key factors you consider when selecting an appropriate HER2-targeted therapy for your patients with HER2+ breast cancer?
- How do you approach the sequencing and combinations of HER2-targeted agents in the adjuvant, neoadjuvant, and metastatic settings?
Advertisement
Related to this article
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Erica S. Alexander, MD, highlights endovascular approaches to venous occlusion, including stenting and thrombolysis, for select patients with NETs.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
In a phase 1 trial, a single intratumoral injection of oncolytic virus SVV-001 with ipilimumab and nivolumab was safe in high-grade neuroendocrine cancers.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5